Ignite Creation Date:
2025-12-25 @ 2:05 AM
Ignite Modification Date:
2025-12-26 @ 1:38 AM
Study NCT ID:
NCT01300260
Status:
COMPLETED
Last Update Posted:
2014-10-07
First Post:
2011-02-03
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Effect of LY2189265 on Insulin Secretion in Response to Intravenous Glucose
Sponsor:
Eli Lilly and Company
Organization:
Study Overview
Official Title:
The Effect of LY2189265 on Insulin Secretion in Response to Intravenous Glucose Infusion
Status:
COMPLETED
Status Verified Date:
2014-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to measure the effect of LY2189265 to increase insulin levels in response to glucose intake.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
Secondary ID Infos
| Secondary ID | Type | Domain | Link | View |
|---|---|---|---|---|
| H9X-MC-GBCI | OTHER | Eli Lilly and Company | View |